NASHVILLE, Tenn. (June 1, 2016) — NextGxDx Inc. (*now Concert Genetics) today announced an agreement with Dartmouth-Hitchcock Medical Center to deliver GeneConnect®, the genetic test utilization management solution that enables healthcare institutions to lower the costs and address the workflow inefficiencies associated with genetic test ordering.
“Genetic testing is the lynchpin of personalized medicine, but with more than 60,000 genetic testing products currently on the market, the field is enormously complex,” said Mark Harris, Ph.D., CEO of NextGxDx. “Dartmouth-Hitchcock is on the forefront of employing genetic test utilization management strategies to manage the rising costs of diagnostics, and we’re excited to assist them in this quest.”
The laboratory management team at Dartmouth-Hitchcock plans to use GeneConnect’s administrative tools to monitor test utilization, track electronic orders and results, and easily compare testing options across reference labs. By incorporating GeneConnect into their ordering workflow, the goal is to support their physicians and genetic counselors in selecting the most clinically effective and cost-efficient laboratory tests for their patients.
The agreement between Dartmouth-Hitchcock and NextGxDx will begin effective immediately.
Dartmouth-Hitchcock (D-H) is a nonprofit academic health system that serves a patient population of 1.2 million in New England. Anchored by Dartmouth-Hitchcock Medical Center in Lebanon, NH, the system includes the Norris Cotton Cancer Center, one of only 41 Comprehensive Cancer Centers in the nation; the Children’s Hospital at Dartmouth-Hitchcock; affiliate hospitals in Keene and New London, NH, and Windsor, VT; and 24 Dartmouth-Hitchcock Clinics that provide ambulatory services across New Hampshire and Vermont. D-H provides access to more than 1,000 primary care doctors and specialists in almost every area of medicine. In partnership with the Audrey and Theodor Geisel School of Medicine at Dartmouth and the White River Junction VA Medical Center in White River Junction, VT, it trains nearly 400 residents and fellows annually, and performs world-class research.
*NextGxDx became Concert Genetics in March 2017.